Baystate Medical Center
- Type
- Teaching hospital
- Where
- SPRINGFIELD, MA
- Medicare CCN
- 220077
- Received
- $477,810 in 88 records, 2022 ($73,139 general, $404,671 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Baystate Medical Center, Inc. Fuzzy (name and state)
- Business registration: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Business registration: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit contractor: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Federal award recipient: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Federal award recipient: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Patent assignee: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Trademark owner: Baystate Medical Center, Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 20 | $73,139 |
| 2022 | Research payment | 68 | $404,671 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 1 | $125,000 | 2022 |
| Medtronic, Inc. | 17 | $113,627 | 2022 |
| GlaxoSmithKline, LLC. | 9 | $41,775 | 2022 |
| Rhythm Pharmaceuticals, Inc. | 16 | $41,670 | 2022 |
| Insmed, Inc. | 9 | $28,925 | 2022 |
| Bio-Rad Laboratories, Inc. | 1 | $24,800 | 2022 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $23,600 | 2022 |
| Genentech, Inc. | 1 | $17,661 | 2022 |
| Chiesi USA, Inc. | 1 | $14,850 | 2022 |
| GENZYME CORPORATION | 6 | $10,692 | 2022 |
| Teleflex LLC | 1 | $6,171 | 2022 |
| Medline Industries LP | 1 | $5,790 | 2022 |
| BIOTRONIK INC. | 2 | $5,650 | 2022 |
| KARL STORZ Endoscopy-America | 1 | $3,494 | 2022 |
| Roche Diagnostics Corporation | 4 | $3,480 | 2022 |
| Hoffmann-La Roche Limited | 1 | $2,970 | 2022 |
| Abbott Laboratories | 2 | $2,570 | 2022 |
| Bolton Medical Inc | 1 | $2,000 | 2022 |
| Edwards Lifesciences Corporation | 1 | $1,249 | 2022 |
| Celgene Corporation | 1 | $850 | 2022 |
| Stryker Corporation | 3 | $548 | 2022 |
| Arrow International, Inc. | 1 | $385 | 2022 |
| NeuroLogica Corporation, a Samsung Company | 1 | $50 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 68 | $404,671 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $24,800 |
| Grant | 2 | $20,000 |
| Debt forgiveness | 9 | $16,138 |
| Long term medical supply or device loan | 2 | $7,420 |
| Travel and Lodging | 2 | $3,110 |
| Space rental or facility fees (teaching hospital only) | 1 | $1,250 |
| Food and Beverage | 3 | $419 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Teleflex LLC | $6,171 | Long term medical supply or device loan | In-kind items and services | WECK Device, SURGICAL | 2022 | |
| 2022-12-31 | Medline Industries LP | $5,790 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $3,494 | Debt forgiveness | In-kind items and services | 2022 | ||
| 2022-12-31 | Edwards Lifesciences Corporation | $1,249 | Long term medical supply or device loan | In-kind items and services | HemoSphere Device, Hemodynamic Monitoring | 2022 | |
| 2022-12-31 | Stryker Corporation | $304 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Stryker Corporation | $150 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Stryker Corporation | $93 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-04 | GlaxoSmithKline, LLC. | $4,175 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2022 | |
| 2022-11-23 | Insmed, Inc. | $4,000 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Tr | 2022 | |
| 2022-11-23 | Insmed, Inc. | $350 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Tr | 2022 | |
| 2022-11-21 | GENZYME CORPORATION | $2,372 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2022 | |
| 2022-11-18 | Celgene Corporation | $850 | Research payment | Cash or cash equivalent | Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double- | 2022 | |
| 2022-11-03 | Medtronic, Inc. | $2,600 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-10-31 | Genentech, Inc. | $17,661 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2022 |
| 2022-10-25 | Medtronic, Inc. | $22,848 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000 | Research payment | Cash or cash equivalent | PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC | 2022 | |
| 2022-10-21 | GlaxoSmithKline, LLC. | $6,009 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2022 | |
| 2022-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $4,000 | Research payment | Cash or cash equivalent | PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC | 2022 | |
| 2022-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000 | Research payment | Cash or cash equivalent | PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC | 2022 | |
| 2022-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000 | Research payment | Cash or cash equivalent | PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC | 2022 | |
| 2022-10-21 | GlaxoSmithKline, LLC. | $2,000 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2022 | |
| 2022-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $1,950 | Research payment | Cash or cash equivalent | PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC | 2022 | |
| 2022-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $1,300 | Research payment | Cash or cash equivalent | PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC | 2022 | |
| 2022-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $350 | Research payment | Cash or cash equivalent | PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC | 2022 | |
| 2022-10-19 | Insmed, Inc. | $17,900 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Tr | 2022 | |
| 2022-10-19 | Insmed, Inc. | $2,500 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Tr | 2022 | |
| 2022-10-12 | Rhythm Pharmaceuticals, Inc. | $4,000 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-10-12 | Rhythm Pharmaceuticals, Inc. | $1,300 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-10-12 | Rhythm Pharmaceuticals, Inc. | $1,300 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-10-12 | Rhythm Pharmaceuticals, Inc. | $650 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-10-12 | Rhythm Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-09-30 | BIOTRONIK INC. | $3,350 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-09-27 | Medtronic, Inc. | $741 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-09-26 | GENZYME CORPORATION | $1,787 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2022 | |
| 2022-09-26 | GENZYME CORPORATION | $715 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2022 | |
| 2022-09-12 | Eli Lilly and Company | $125,000 | Research payment | Cash or cash equivalent | 2022 | ||
| 2022-08-31 | Medtronic, Inc. | $15,546 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-08-24 | GlaxoSmithKline, LLC. | $8,000 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2022 | |
| 2022-08-24 | GlaxoSmithKline, LLC. | $5,087 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2022 | |
| 2022-08-15 | GENZYME CORPORATION | $3,055 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2022 | |
| 2022-08-15 | GENZYME CORPORATION | $260 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2022 | |
| 2022-08-01 | Medtronic, Inc. | $5,757 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-08-01 | Medtronic, Inc. | $5,757 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-07-29 | Arrow International, Inc. | $385 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-07-25 | Rhythm Pharmaceuticals, Inc. | $435 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-022 | 2022 |
| 2022-07-18 | Rhythm Pharmaceuticals, Inc. | $4,948 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-014 | 2022 |
| 2022-07-05 | NeuroLogica Corporation, a Samsung Company | $50 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-06-27 | Roche Diagnostics Corporation | $1,754 | Travel and Lodging | In-kind items and services | BCM for cobas 8100 Device, Core Lab | 2022 | |
| 2022-06-27 | Roche Diagnostics Corporation | $157 | Food and Beverage | In-kind items and services | BCM for cobas 8100 Device, Core Lab | 2022 | |
| 2022-06-24 | Medtronic, Inc. | $10,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-06-17 | Medtronic, Inc. | $14,027 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-06-15 | Rhythm Pharmaceuticals, Inc. | $15,000 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-06-15 | Rhythm Pharmaceuticals, Inc. | $3,000 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-06-15 | Rhythm Pharmaceuticals, Inc. | $3,000 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-06-15 | Rhythm Pharmaceuticals, Inc. | $2,500 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-06-15 | Rhythm Pharmaceuticals, Inc. | $425 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-06-15 | Rhythm Pharmaceuticals, Inc. | $350 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-034 | 2022 |
| 2022-06-02 | Rhythm Pharmaceuticals, Inc. | $1,662 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-022 | 2022 |
| 2022-05-20 | Medtronic, Inc. | $850 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-05-20 | Medtronic, Inc. | $850 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-05-20 | Medtronic, Inc. | $802 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-05-20 | Medtronic, Inc. | $802 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-05-16 | Medtronic, Inc. | $10,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-05-12 | Insmed, Inc. | $1,375 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2022 | |
| 2022-05-12 | Insmed, Inc. | $450 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2022 | |
| 2022-05-10 | Insmed, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | In-kind items and services | 2022 | ||
| 2022-05-05 | Bolton Medical Inc | $2,000 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Device | RelayPro-A IP-0015-16 | 2022 |
| 2022-04-27 | Medtronic, Inc. | $10,298 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-04-27 | Medtronic, Inc. | $10,298 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-04-19 | BIOTRONIK INC. | $2,300 | Research payment | Cash or cash equivalent | Orsiro Mission Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2022 |
| 2022-04-11 | GlaxoSmithKline, LLC. | $2,534 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2022 | |
| 2022-04-11 | Roche Diagnostics Corporation | $1,356 | Travel and Lodging | In-kind items and services | cobas 8000 Core Unit Device, Core Lab | 2022 | |
| 2022-04-11 | Roche Diagnostics Corporation | $211 | Food and Beverage | In-kind items and services | cobas 8000 Core Unit Device, Core Lab | 2022 | |
| 2022-04-05 | Insmed, Inc. | $650 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2022 | |
| 2022-04-05 | Insmed, Inc. | $450 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brenso | 2022 | |
| 2022-04-04 | Chiesi USA, Inc. | $14,850 | Research payment | Cash or cash equivalent | CUROSURF Drug, NEONATOLOGY | A STUDY IN PRETERM NEONATES WITH RDS TO COMPARE CUROSURF ADMINISTRATION THROUGH LISA AND CONVENTIONAL ADMINISTRATION (LI | 2022 |
| 2022-03-31 | Rhythm Pharmaceuticals, Inc. | $650 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-014 | 2022 |
| 2022-03-29 | Medtronic, Inc. | $1,225 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-03-29 | Medtronic, Inc. | $1,225 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-03-22 | Hoffmann-La Roche Limited | $2,970 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2022 |
| 2022-03-22 | Abbott Laboratories | $1,285 | Debt forgiveness | Cash or cash equivalent | ARCHITECT Device, Core Diagnostics | 2022 | |
| 2022-03-22 | Abbott Laboratories | $1,285 | Debt forgiveness | Cash or cash equivalent | ARCHITECT Device, Core Diagnostics | 2022 | |
| 2022-03-16 | Rhythm Pharmaceuticals, Inc. | $1,950 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-022 | 2022 |
| 2022-03-09 | Bio-Rad Laboratories, Inc. | $24,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | BioPlex 2200 Device, BioPlex | 2022 | |
| 2022-02-22 | GlaxoSmithKline, LLC. | $4,508 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2022 | |
| 2022-02-22 | GENZYME CORPORATION | $2,502 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2022 | |
| 2022-02-14 | GlaxoSmithKline, LLC. | $4,934 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2022 | |
| 2022-01-24 | GlaxoSmithKline, LLC. | $4,526 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Springfield, MA, county Hampden County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Springfield, MA | County Hampden County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 154,749 | 462,815 | 7,044,056 |
| Population, 2020 census P1 | 155,929 | 465,825 | 7,029,917 |
| Median age B01002 | 33.7 | 40.0 | 40.0 |
| Under 18 B01001 | 24.2% | 20.9% | 19.4% |
| 65 and over B01001 | 13.2% | 18.3% | 17.9% |
| Households B11001 | 57,772 | 184,471 | 2,785,042 |
| Foreign born B05002 | 10.5% | 9.4% | 18.0% |
| Median household income B19013 | $52,656 | $71,306 | $103,960 |
| Median family income B19113 | $66,045 | $91,397 | $131,675 |
| Per capita income B19301 | $27,337 | $38,219 | $57,897 |
| Poverty rate B17001 | 25.8% | 16.3% | 10.0% |
| Unemployment rate B23025 | 8.7% | 6.0% | 5.2% |
| Civilian labor force B23025 | 69,390 | 226,771 | 3,911,446 |
| Mean commute (minutes) B08013 | 20.2 | 22.7 | 29.1 |
| Bachelor's degree or higher B15003 | 20.5% | 29.3% | 47.3% |
| Housing units B25001 | 62,217 | 197,591 | 3,030,406 |
| Owner-occupied B25003 | 49.6% | 62.2% | 62.5% |
| Renters B25003 | 50.4% | 37.8% | 37.5% |
| Median home value B25077 | $245,000 | $298,800 | $562,100 |
| Median gross rent B25064 | $1,144 | $1,136 | $1,762 |
| White, not Hispanic B03002 | 27.8% | 59.3% | 66.6% |
| Black B03002 | 17.5% | 7.6% | 6.4% |
| Hispanic or Latino B03002 | 48.6% | 27.0% | 13.3% |
| Asian B03002 | 2.7% | 2.5% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Springfield, MA.
Comments